TGM2 and cranioectodermal dysplasia: Similarly, another TG2 inhibitor, GSK-3915393, was being studied for CeD, but after phase 1 completion, the study was discontinued by the sponsor (NCT04604795) [70] and is currently only being studied for Idiopathic Pulmonary Fibrosis [71].